A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
Study Details
Study Description
Brief Summary
The purpose of this study is to test the drug RAD001 in combination with other chemotherapy drugs, Carboplatin and Cetuximab. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination.
The investigators will test the safety of RAD001 in combination with Carboplatin and Cetuximab and see what effects (good and/or bad) it has on your cancer, and find the highest dose of RAD001 that can be given without causing bad side effects. The doses of Carboplatin and Cetuximab will not be varied as both these drugs are considered to be part of the current standard of care for patients with your condition.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: A Treatment arm with carboplatin, cetuximab and RAD001 |
Drug: Carboplatin
Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
Other Names:
Drug: Cetuximab
Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
Other Names:
Drug: RAD001
For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and Neck Cancer [Within the first 21 days of therapy]
This phase 1 clinical trial used a standard 3 + 3 design. Four dose levels of everolimus were planned to be evaluated, and the standard 3 + 3 design with dose de-escalation was used in the trial. Namely, 3 patients were assigned to starting dose level 1. If no dose-limiting toxicity (DLT) was observed, the trial proceeded to the next dose level, and another cohort of 3 patients was enrolled. If at least 2 of the 3 patients experienced at least 1 DLT, then the dose level decreased; otherwise, if only 1 patient experienced DLT, then 3 more patients were enrolled at the same dose level. If none of the 3 additional patients experienced DLT, the dose was escalated; otherwise, the dose level decreased. Dose reduction continued until a dose level was reached at which 6 patients had been treated and at most 1 DLT was observed.
Secondary Outcome Measures
- Progression-free Survival (PFS) [The time of PFS was calculated as the time from study enrollment to the disease progression date, death date, or last contact, whichever came first, up to 25 months]
Objective tumor responses were assessed every 2 cycles of chemotherapy with computed tomography or positron emission tomography/ computed tomography scans in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.
-
Histologically or cytologically proven squamous cell carcinoma of the head and neck (SCCHN).
-
Patients with recurrent, refractory or metastatic squamous cell carcinoma of oral cavity, oropharynx and larynx, hypopharynx or paranasal sinus, and unknown primary SCCHN who failed to respond to, or relapsed from prior chemoradiotherapy for definitive treatment of disease.
-
Evaluable locoregional and/or metastatic disease according to RECIST criteria (see Section 6) that is not appropriate for treatment by primary surgical resection or radiotherapy.
-
Patients may not have had prior chemotherapy for recurrent or metastatic disease.
-
Patients must not be candidates for curative therapy.
-
Age ≥ 18 years.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
-
Life expectancy of ≥ 4 months.
-
Adequate bone marrow, liver and renal function as assessed by the following:
-
Hemoglobin ≥ 9.0/dl
-
Absolute-neutrophil count (ANC ) ≥ 1500/mm3
-
Platelet count ≥ 100,000/mm3
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
-
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
-
International normalized ratio (INR) ≤ 1.5 or a prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight (LMW) heparin for > 2 weeks at time of randomization)
-
Creatinine ≤ 1.5 x ULN
-
Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
-
Women of childbearing potential must have a negative pregnancy test within 7 days prior to first receiving investigational product. Sexually active women of childbearing potential (WOCBP) must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control. All WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study participation.
-
Signed informed consent prior to beginning protocol specific procedures. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial.
Exclusion Criteria:
-
History of prior malignancy within the past 5 years except for curatively treated basal cell carcinoma and squamous cell carcinoma of the skin, cervical intraepithelial neoplasia (CIN) or localized prostate cancer with a current prostate-specific antigen (PSA) < 1.0 mg/dL on 2 successive evaluations at least 3 months apart, with the most recent evaluation within 4 weeks of study entry.
-
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.
-
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.).
-
Prior treatment with any investigational drug within the preceding 4 weeks.
-
Any unresolved toxicity (except alopecia) greater than NCI-Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 grade 2 from prior systemic anticancer therapy.
-
Patients who have received prior treatment with a mammalian target of rapamycin (mTOR) inhibitor (sirolimus, temsirolimus, everolimus).
-
Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients, or to cetuximab.
-
Prior therapy with Cetuximab will be allowed provided it was part of definitive therapy and not part of treatment for recurrent or metastatic disease.
-
Prior severe infusion reaction to a monoclonal antibody.
-
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
-
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period.
-
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study.
-
Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
-
Symptomatic congestive heart failure of New York heart Association Class III or IV
-
Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
-
Severely impaired lung function as defined as spirometry and diffusing capacity of lung for carbon monoxide (DLCO) that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
-
Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
-
Active (acute or chronic) or uncontrolled severe infections
-
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
-
Abnormal liver function tests (LFTs) as follows: total bilirubin (TB) > 1.5x ULN, alanine aminotransferase (ALT) > 1.25x ULN, and/or alkaline phosphatase > 2.5 x ULN (except when LFTs attributed to metastatic SCCHN, in which case, TB, ALT and alkaline phosphatase must be ≤ NCI-CTCAE, v3.0 grade 1).
-
Absolute neutrophil count < 1000/mm3 or platelets < 100,000/mm3.
-
A known history of HIV seropositivity.
-
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
-
Patients with an active, bleeding diathesis.
-
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (WOCBP must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001).
-
History of noncompliance to medical regimens.
-
Patients unwilling to or unable to comply with the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Emory University Winship Cancer Institute | Atlanta | Georgia | United States | 30322 |
Sponsors and Collaborators
- Emory University
- Novartis
Investigators
- Principal Investigator: Nabil F. Saba, MD, Emory University Winship Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB00040298
- WCI1761-09
Study Results
Participant Flow
| Recruitment Details | After institutional review board approval, the study enrolled 20 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Carboplatin, Cetuximab and Everolimus |
|---|---|
| Arm/Group Description | Carboplatin, cetuximab and RAD001 (everolimus) Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis |
| Period Title: Overall Study | |
| STARTED | 20 |
| COMPLETED | 13 |
| NOT COMPLETED | 7 |
Baseline Characteristics
| Arm/Group Title | Carboplatin, Cetuximab and Everolimus |
|---|---|
| Arm/Group Description | Carboplatin, cetuximab and RAD001 (everolimus) Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis |
| Overall Participants | 20 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
11
55%
|
| >=65 years |
9
45%
|
| Sex: Female, Male (Count of Participants) | |
| Female |
2
10%
|
| Male |
18
90%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
0
0%
|
| Asian |
1
5%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
1
5%
|
| White |
14
70%
|
| More than one race |
0
0%
|
| Unknown or Not Reported |
4
20%
|
| Region of Enrollment (participants) [Number] | |
| United States |
20
100%
|
Outcome Measures
| Title | To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and Neck Cancer |
|---|---|
| Description | This phase 1 clinical trial used a standard 3 + 3 design. Four dose levels of everolimus were planned to be evaluated, and the standard 3 + 3 design with dose de-escalation was used in the trial. Namely, 3 patients were assigned to starting dose level 1. If no dose-limiting toxicity (DLT) was observed, the trial proceeded to the next dose level, and another cohort of 3 patients was enrolled. If at least 2 of the 3 patients experienced at least 1 DLT, then the dose level decreased; otherwise, if only 1 patient experienced DLT, then 3 more patients were enrolled at the same dose level. If none of the 3 additional patients experienced DLT, the dose was escalated; otherwise, the dose level decreased. Dose reduction continued until a dose level was reached at which 6 patients had been treated and at most 1 DLT was observed. |
| Time Frame | Within the first 21 days of therapy |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Everolimus Dose Level 1 DLT | Everolimus Dose Level -1 DLT |
|---|---|---|
| Arm/Group Description | Carboplatin, cetuximab and RAD001 (everolimus) at Dose Level 1 (2.5 mg/day) | Carboplatin, cetuximab and RAD001 (everolimus) at Dose Level -1 (2.5 mg every other day) |
| Measure Participants | 6 | 6 |
| Number [participants] |
2
10%
|
1
NaN
|
| Title | Progression-free Survival (PFS) |
|---|---|
| Description | Objective tumor responses were assessed every 2 cycles of chemotherapy with computed tomography or positron emission tomography/ computed tomography scans in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria. |
| Time Frame | The time of PFS was calculated as the time from study enrollment to the disease progression date, death date, or last contact, whichever came first, up to 25 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Carboplatin, Cetuximab and Everolimus |
|---|---|
| Arm/Group Description | Carboplatin, cetuximab and RAD001 (everolimus) Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis |
| Measure Participants | 13 |
| Median (Full Range) [months] |
8.15
|
Adverse Events
| Time Frame | Up to 25 months | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Carboplatin, Cetuximab and Everolimus | |
| Arm/Group Description | Carboplatin, cetuximab and RAD001 (everolimus) Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis | |
All Cause Mortality |
||
| Carboplatin, Cetuximab and Everolimus | ||
| Affected / at Risk (%) | # Events | |
| Total | / (NaN) | |
Serious Adverse Events |
||
| Carboplatin, Cetuximab and Everolimus | ||
| Affected / at Risk (%) | # Events | |
| Total | 2/20 (10%) | |
| Gastrointestinal disorders | ||
| Nausea and vomiting | 1/20 (5%) | |
| Hemoptysis and death | 1/20 (5%) | |
Other (Not Including Serious) Adverse Events |
||
| Carboplatin, Cetuximab and Everolimus | ||
| Affected / at Risk (%) | # Events | |
| Total | 7/20 (35%) | |
| Blood and lymphatic system disorders | ||
| Neutropenia | 7/20 (35%) | |
| Hypokalemia | 4/20 (20%) | |
| Leukopenia | 4/20 (20%) | |
| Hypophosphatemia | 3/20 (15%) | |
| Hyponatremia | 2/20 (10%) | |
| Anemia | 1/20 (5%) | |
| Thrombocytopenia | 1/20 (5%) | |
| Hypophosphatemia | 6/20 (30%) | |
| Gastrointestinal disorders | ||
| Diarrhea | 1/20 (5%) | |
| General disorders | ||
| Fatigue | 2/20 (10%) | |
| Immune system disorders | ||
| Anaphylaxis | 4/20 (20%) | |
| Infections and infestations | ||
| Sepsis | 1/20 (5%) | |
| Metabolism and nutrition disorders | ||
| Hyperglycemia | 5/20 (25%) | |
| Respiratory, thoracic and mediastinal disorders | ||
| Aspiration pneumonia | 1/20 (5%) | |
| Skin and subcutaneous tissue disorders | ||
| Rash | 3/20 (15%) | |
| Mucositis | 3/20 (15%) | |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Nabil F. Saba, MD |
|---|---|
| Organization | Emory University |
| Phone | 404-778-1900 |
| nfsaba@emory.edu |
- IRB00040298
- WCI1761-09